Clinical Trial Update: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating haploidentical donor natural killer cell therapy using CD3/CD19-depleted or CD3-depleted/CD56-selected NK cells for older patients wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD3/CD19-depleted or CD3-depleted/CD56-selected haploidentical donor natural killer cell therapy

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: WITHDRAWN